<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03080792</url>
  </required_header>
  <id_info>
    <org_study_id>PRESENT-P/ S-030/2016</org_study_id>
    <nct_id>NCT03080792</nct_id>
  </id_info>
  <brief_title>Pre-Exercise for Allogeneic Stem Cell Transplant Patients</brief_title>
  <acronym>PRESENT-P</acronym>
  <official_title>Pre-Exercise for Allogeneic Stem Cell Transplant Patients: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PRESENT-P study is a one-arm exercise intervention study for hematological cancer&#xD;
      patients prior allogeneic stem cell transplantation (allo-HCT). This pilot study will&#xD;
      investigate in a prehabilitation approach the safety and feasibility of high-intensity&#xD;
      exercise program directly prior transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The major objective of PRESENT-P is to investigate the feasibility and safety of a high&#xD;
      intensity endurance exercise training (HIIT) and progressive resistance exercise prior&#xD;
      allo-HCT. This multicenter pilot study will include n=30 patients. Patients perform two&#xD;
      supervised exercise sessions per week. Recruitment take place 6-12 weeks prior allogeneic&#xD;
      stem cell transplantation. Further aims of this pilot study are: to estimate the number of&#xD;
      eligible patients, evaluate the recruitment procedure, and to explore the effect of HIIT&#xD;
      prior allo-HCT on maximal oxygen uptake (VO2peak),submaximal endurance capacity, muscle&#xD;
      strength, patient-reported-outcomes including QoL and physical functioning.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment difficult&#xD;
  </why_stopped>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of supervised high-intensity aerobic exercise training and high-intensity resistance training prior allo-HCT in hematological cancer patients. Measured as adherence to the training protocol</measure>
    <time_frame>4-12 weeks</time_frame>
    <description>Adherence is defined as &gt;50% of prescribed exercise sessions completed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of supervised high-intensity exercise aerobic exercise training and high-intensity resistance training prior allo-HCT in hematological cancer</measure>
    <time_frame>4-12 weeks</time_frame>
    <description>Minor and Major adverse events that are related to the exercise intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in maximal oxygen uptake (VO2peak), assessed in a maximal incremental exercise test (CPET) on a cycle ergometer</measure>
    <time_frame>4-12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in submaximal endurance performance, assessed in a 6-minute walk test (6MWT)</measure>
    <time_frame>4-12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximal voluntary isometric contraction (MVIC) in a stationary dynamometer test</measure>
    <time_frame>4-12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximal voluntary isometric hand-grip strength</measure>
    <time_frame>4-12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QoL)</measure>
    <time_frame>4-12 weeks</time_frame>
    <description>European Research and Treatment in Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fatigue</measure>
    <time_frame>4-12 weeks</time_frame>
    <description>Multidimensional Fatigue Inventory, MFI 20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depression</measure>
    <time_frame>4-12 weeks</time_frame>
    <description>Center for Epidemiologic Studies Depression Scale, CES-D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition</measure>
    <time_frame>4-12 weeks</time_frame>
    <description>Bioelectrical impendance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the number of eligible patients</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of recruitment procedures</measure>
    <time_frame>12 month</time_frame>
    <description>Description of possible recruiting procedures in the ambulatory and stationary setting.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Cancer, Hematological</condition>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise Intervention, moderate to high-intensity endurance and resistance exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Experimental: moderate to high-intensity exercise</intervention_name>
    <description>2x per week endurance exercise (continuous moderate and high intensity intervall training on a cycle ergometer) and progressive resistance training (machine based hypertrophy training)</description>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hematological cancer, e.g. AML, CLL, MM&#xD;
&#xD;
          -  Scheduled for allo-HCT at the University Clinic Heidelberg or other cooperation sites&#xD;
             within the next 4-12 weeks&#xD;
&#xD;
          -  Patients ≥ 18 years of age&#xD;
&#xD;
          -  Sufficient German language skills&#xD;
&#xD;
          -  Willing/ able to train at the provided exercise facilities twice per week and to take&#xD;
             part in the scheduled testing&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart insufficiency &gt; NYHA III or uncertain arrhythmia&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Severe renal dysfunction (GFR &lt; 30%, Creatinine&gt; 3mg/dl)&#xD;
&#xD;
          -  Reduced standing or walking ability&#xD;
&#xD;
          -  Insufficient hematological capacity (either hemoglobin value below 8 g/dl or&#xD;
             thrombocytes below 30.000/µL)&#xD;
&#xD;
          -  Any other comorbidities that preclude participation in the exercise programs&#xD;
&#xD;
          -  Engaging in systematic intense exercise training (at least 1h twice per week)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Wiskemann, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University Hospital, National Center for Tumor Disease, Division of Medical Oncology, Working Group Exercise Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colone</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCT Frankfurt / Hospital North-West</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center - University Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heidelberg University Hospital</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 16, 2016</study_first_submitted>
  <study_first_submitted_qc>March 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2017</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Joachim Wiskemann</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>stem cell transplantation</keyword>
  <keyword>exercise</keyword>
  <keyword>high intensity interval training</keyword>
  <keyword>resistance training</keyword>
  <keyword>physical fitness</keyword>
  <keyword>cancer</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

